Nectin Therapeutics Adds Combination Therapy Arm and Expands Sites in Phase 1 Clinical Trial of Its First-in-Class Anti-PVR Immune-Oncology Agent by cyarema@rpagency.com | Dec 18, 2023 | Nectin
Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma by cyarema@rpagency.com | May 16, 2023 | Nectin
Israeli Biotech Company Begins Trial For Cancer Immuno-Oncology Solution by rpadmin | Dec 6, 2022 | Nectin
MD Anderson VC Arm Joins $25M Funding Round For Cancer Drug Company by rpadmin | Dec 6, 2022 | Nectin
Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors by rpadmin | Dec 6, 2022 | Nectin